Clinical Trial Update: Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

An early-phase study evaluating SIR-Spheres (yttrium-90 microspheres) in combination with sorafenib as first-line therapy for unresectable hepatocellular carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SIR-Spheres (yttrium-90 glass microspheres)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Singapore Clinical Research Institute | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED